For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
August 27, 2001
- Launching of Tarivid Generics Postponed Due to Patent Problems
August 27, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 27, 2001
- Nosan Corporation Ties Up with Midwest Research Institute
August 27, 2001
- Quality Reevaluation Enters Step 4 for 28 Ingredients
August 27, 2001
- MEDICAL DEVICE NEWS IN BRIEF
August 27, 2001
- Kirin Forms Research Alliance with Hyseq
August 27, 2001
- Use of Orange Book, Rx in Generic Name Recommended for Promotion of Generics: EAD Director
August 27, 2001
- Fujirebio, diaDexus Tie Up to Develop Cancer Diagnostic Agents
August 27, 2001
- Takeda, Pharmacia to Launch Smoking Cessation Aid Nicorette in September
August 20, 2001
- Tiracoxib Designated as Orphan for Familial Adenomatous Polyposis
August 20, 2001
- Asahi Kasei Licenses Out Fasudil to Schering AG
August 20, 2001
- Genomic Drug Discovery, Tailor-Made Medicine to Receive Top Priority in FY2002 Budgeting
August 20, 2001
- Takeda, Bayer to Discuss with Korosho on Cerivastatin
August 20, 2001
- Generics of 20 Drugs to Be Tested: 14th Quality Reevaluation
August 20, 2001
- Daiichi to Clear Goals for 1st Half of FY2001: President Morita
August 20, 2001
- 29 Mono-drugs, 1 Combination Designated: 15th Quality Reevaluation
August 20, 2001
- FPMAJ Presents Opinions on Proposed Drug Classification System
August 20, 2001
- Mean Life Expectancy Increases to 77.64 years for Men, 84.62 years for Women
August 20, 2001
- WORLD NEWS IN BRIEF
August 20, 2001
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…